{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/whitlow-staphylococcal-herpetic/prescribing-information/aciclovir/","result":{"pageContext":{"chapter":{"id":"ae3b006b-c4df-5e15-aee8-5ac6c019923f","slug":"aciclovir","fullItemName":"Aciclovir","depth":2,"htmlHeader":"<!-- begin field fde57f39-7a4d-4e03-a72d-d41affcf43c1 --><h2>Aciclovir</h2><!-- end field fde57f39-7a4d-4e03-a72d-d41affcf43c1 -->","summary":"","htmlStringContent":"<!-- begin item 9385221b-f881-41a3-8534-a30a19cc3334 --><!-- end item 9385221b-f881-41a3-8534-a30a19cc3334 -->","topic":{"id":"ac1c1826-f21a-5abd-8e92-1e2db8ea28ea","topicId":"f989f159-ab30-4d16-b9df-b534a9fd4192","topicName":"Whitlow (staphylococcal and herpetic)","slug":"whitlow-staphylococcal-herpetic","lastRevised":"Last revised in January 2021","chapters":[{"id":"8442fc1d-a788-50ac-a15a-9c2c91e8589b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"895f3b40-8720-5843-8910-fe1b288857a8","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7e4ec3c7-b080-5717-b1c3-0003acba46e5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7c70fe97-728d-5bc4-94c2-1996b37ee0f9","slug":"changes","fullItemName":"Changes"},{"id":"4889bd92-0b32-558d-8390-80d27fbcce73","slug":"update","fullItemName":"Update"}]},{"id":"1a79ca57-c8cc-5044-ac68-5d220bab1460","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"684fde23-e839-56ff-8b7f-8e6863b2c42d","slug":"goals","fullItemName":"Goals"},{"id":"97b35971-df6d-5ecb-a631-dfcf580e1fa9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"12181a78-1b8d-58b4-884a-8930d15cf654","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"521ae353-eea7-5e2f-bd0e-b292540b72eb","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"87054726-2905-5ac0-b369-92e5fd68a177","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2b6dffce-588f-532a-9776-7e3ff32005ee","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"2d957194-aa56-5cb7-98aa-cb3d8f988743","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f0191f08-fb2e-5c5b-957c-8a190d5b4539","slug":"definition","fullItemName":"Definition"},{"id":"b8b2a1f1-fbc7-5b8f-a5c4-c0e9409d566f","slug":"causes","fullItemName":"Causes"},{"id":"c7287d38-e377-5d65-9c4f-3201369e0213","slug":"prevalence","fullItemName":"Prevalence"},{"id":"adc749af-b4d0-50c9-9996-b470b8f76613","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d632b72f-6e73-58ee-9d8d-21b6101f6394","slug":"prognosis","fullItemName":"Prognosis"},{"id":"faed0075-1878-5f17-abc9-9316eaa064e7","slug":"complications","fullItemName":"Complications"}]},{"id":"96e4a200-e348-5fab-89e2-f0ba789b7b72","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"910097a7-71be-5c13-949e-0be7c045df35","slug":"diagnosis-of-whitlow","fullItemName":"Diagnosis of whitlow"},{"id":"6f468174-fafe-579c-90f9-500f22e70e17","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"8ac8a269-e748-5e7e-9b74-8fb5661d1ae5","fullItemName":"Management","slug":"management","subChapters":[{"id":"ac7fabf7-d7b7-5fb2-a0a6-1d28e040e2c8","slug":"staphylococcal-whitlow","fullItemName":"Scenario: Staphylococcal whitlow"},{"id":"bde8ed40-6fd8-505e-86bb-d75eac34743f","slug":"herpetic-whitlow","fullItemName":"Scenario: Herpetic whitlow"}]},{"id":"5d7afad5-ae43-5c2e-8ecf-6df00603ca01","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ae3b006b-c4df-5e15-aee8-5ac6c019923f","slug":"aciclovir","fullItemName":"Aciclovir"},{"id":"46185de6-35ef-5e34-a1fd-e0d1463c538e","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"2a50e932-9f92-5a94-a8e5-aab1ee400b9d","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"0ad07f56-519a-59d6-90bc-6b6d6081e6ab","slug":"flucloxacillin","fullItemName":"Flucloxacillin"}]},{"id":"98ea0d83-9b18-58b4-aa73-7a50d72e15ba","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4dd77db6-a4e1-5304-8a06-196e7628f612","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0191f79d-0e03-554c-b0bd-4b592d452f4a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3e95c155-472c-52d0-9098-a797cec2ad27","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f39c5716-7472-576a-be8f-7d705a0dc4dd","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"73c24405-a40a-51ba-ac01-8dd957f7c657","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7005b3b9-63e2-5222-840e-73155dac338e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"18dd81bb-78d7-57f1-9fc9-24aa775b3c9d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5d7afad5-ae43-5c2e-8ecf-6df00603ca01","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"026868c4-29bc-5fe1-aa7b-1ab4bca34573","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 20be8e9d-7ada-4171-b68b-d7c1c3be4ccd --><h3>What dose of aciclovir should I prescribe?</h3><!-- end field 20be8e9d-7ada-4171-b68b-d7c1c3be4ccd -->","summary":"","htmlStringContent":"<!-- begin item c538b387-9858-402d-bdc1-ac6ee8ec2e7b --><!-- begin field f4d2a1a6-4c52-47c5-8881-e527394d5d92 --><ul><li>For adults and children older than 2 years of age — prescribe 200 mg five times daily (at approximately four hourly intervals during the day, omitting the night time dose) for 5 days.</li><li>For children 1 month to 2 years of age — prescribe 100 mg five times daily (at approximately four hourly intervals during the day, omitting the night time dose) for 5 days.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">BNF 71, 2016</a>]</p><!-- end field f4d2a1a6-4c52-47c5-8881-e527394d5d92 --><!-- end item c538b387-9858-402d-bdc1-ac6ee8ec2e7b -->","subChapters":[]},{"id":"e257ab46-3b9e-5577-9240-1ddd7e26238d","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field ac2112fe-75ae-4771-a6a6-8fbc3023f08f --><h3>What are the contraindications and cautions for aciclovir?</h3><!-- end field ac2112fe-75ae-4771-a6a6-8fbc3023f08f -->","summary":"","htmlStringContent":"<!-- begin item a04993ee-10a8-4d6e-8168-7124c840303b --><!-- begin field 6863755b-f2e6-4c2e-97f2-955bdfda03b1 --><ul><li><strong>Do not prescribe aciclovir</strong> to a person with a known allergy to aciclovir or valaciclovir.</li><li><strong>Prescribe aciclovir with caution</strong> in a person who: <ul><li>Is elderly.</li><li>Has underlying neurological abnormalities.</li><li>Has severe liver or electrolyte abnormalities.</li><li>Has significant hypoxia.</li><li>Has renal impairment — advise the person to maintain adequate hydration. For herpes simplex infection, use the normal oral dose every 12 hours if the person's estimated Glomerular Filtration Rate (eGFR) is less than 10 mL/minute/1.73 m<sup>2</sup>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">BNF 71, 2016</a>]</p><!-- end field 6863755b-f2e6-4c2e-97f2-955bdfda03b1 --><!-- end item a04993ee-10a8-4d6e-8168-7124c840303b -->","subChapters":[]},{"id":"b8a8dba6-1e42-5e86-9039-00a4e5b90708","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 756d00ac-dbfe-4b8b-9158-7db7c50828a6 --><h3>What are the adverse effects of aciclovir?</h3><!-- end field 756d00ac-dbfe-4b8b-9158-7db7c50828a6 -->","summary":"","htmlStringContent":"<!-- begin item a6bcd4da-0bf6-455b-bd28-6ba6f4269e35 --><!-- begin field 16455c46-8a7d-4fec-b9fa-8a4efd8ae348 --><ul><li>Aciclovir is generally well tolerated. </li><li>However, it may cause gastrointestinal adverse effects, such as nausea, vomiting, diarrhoea, and abdominal pain. Headache, dizziness, and skin rashes (including photosensitivity and urticaria) have also been commonly reported.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">BNF 71, 2016</a>]</p><!-- end field 16455c46-8a7d-4fec-b9fa-8a4efd8ae348 --><!-- end item a6bcd4da-0bf6-455b-bd28-6ba6f4269e35 -->","subChapters":[]},{"id":"97d4210b-f48a-5f82-9a7a-6d4bbc327ada","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 8af9c1bb-3446-435c-bf31-c7229f198c4b --><h3>What are the drug interactions with aciclovir?</h3><!-- end field 8af9c1bb-3446-435c-bf31-c7229f198c4b -->","summary":"","htmlStringContent":"<!-- begin item c36fdd28-3af2-4183-9232-6f00936a0481 --><!-- begin field 81f53176-2341-4dbd-b6ae-8963db148ea1 --><ul><li>There are no clinically significant drug interactions with aciclovir.<br></li><li>However, if other nephrotoxic drugs are used, the risk of renal impairment is increased.</li></ul><div>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">ABPI, 2015a</a>]<br></div><!-- end field 81f53176-2341-4dbd-b6ae-8963db148ea1 --><!-- end item c36fdd28-3af2-4183-9232-6f00936a0481 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}